Patients receiving radical radiotherapy for very high‐risk/locally advanced prostate cancer should receive 24 months of Abiraterone + Prednisolone (or alternative novel Androgen Receptor Targeted Agent as evidence emerges) in addition to ADT? This evidence concerns the gene AR and prostate cancer.